39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

Key Takeaways Explain This Topic AI

Actinic keratosis (AK) is a UV-induced premalignant intraepidermal keratinocyte proliferation that presents as a gritty, rough erythematous papule ('feels like sandpaper') on sun-damaged skin; isolated lesions are treated with liquid nitrogen cryotherapy, while widespread field damage requires field therapy with topical 5-fluorouracil (5-FU 5% BID for 2-4 weeks) or imiquimod.

Basal cell carcinoma (BCC) is the most common cutaneous malignancy, characterized by slow local tissue invasion and negligible metastatic potential (<0.1%); nodular BCC presents with a pearly, translucent papule with arborizing telangiectasias and rolled borders, whereas superficial BCC presents as an erythematous scaly patch; standard low-risk lesions are excised with 4 mm margins, while high-risk lesions ('H-zone' of face, morpheaform histology, recurrent) mandate Mohs micrographic surgery.

Cutaneous squamous cell carcinoma (SCC) is an invasive keratinocyte malignancy presenting as a firm, indurated, hyperkeratotic or ulcerated plaque/nodule; while overall metastasis is 2% to 5%, high-risk lesions (vermilion lip, ear, perineum, scars, diameter >2 cm, or immunosuppressed organ transplant recipients) carry markedly elevated metastatic potential and require wide excision (4-6 mm margins) or Mohs surgery.

Melanoma clinical evaluation relies on the ABCDE criteria (Asymmetry, Border irregularity, Color variegation, Diameter >=6 mm, and Evolving—the most sensitive indicator) and the 'Ugly Duckling' sign; any suspicious pigmented lesion requires complete narrow excisional biopsy with 1-3 mm margins extending into subcutaneous fat—superficial shave biopsy is strictly contraindicated because it transects the base and prevents accurate Breslow depth staging.

Breslow depth is the single most powerful prognostic determinant in localized melanoma and dictates surgical wide excision margins: in situ requires 0.5 cm margins, <1.0 mm requires 1.0 cm margins, 1.0-2.0 mm requires 1-2 cm margins, and >2.0 mm requires 2.0 cm margins; sentinel lymph node biopsy (SLNB) is indicated for Breslow depth >=1.0 mm or 0.8-1.0 mm with high-risk features (ulceration, high mitotic rate).

Last updated: September 2026

Actinic Keratosis: Pathogenesis & Sandpaper Morphology

Actinic keratosis (AK, solar keratosis) is the most common premalignant cutaneous neoplasm encountered in outpatient medicine, affecting more than 40 million Americans. It represents an early, intraepidermal stage in the biological continuum toward invasive cutaneous squamous cell carcinoma.

Molecular Pathogenesis & UV Carcinogenesis

UVB Radiation (290-320 nm) : The primary etiological driver. UVB induces specific signature mutations characterized by cytosine-to-thymine ( C-to-T ) and CC-to-TT dipyrimidine transitions within the TP53 tumor suppressor gene of basal epidermal keratinocytes.

Clonal Proliferation : Loss of p53-mediated DNA repair and apoptosis permits dysplastic atypical keratinocytes to proliferate. These atypical cells display nuclear pleomorphism, hyperchromasia, disordered architectural maturation, and loss of polarity, remaining strictly confined above the basement membrane (intraepidermal).

Clinical Presentation: The "Sandpaper" Lesion

Morphology : An ill-defined, erythematous to yellowish-brown macule or thin papule topped by a rough, dry, adherent scale.

Board Exam Classic Clue : "Feels like coarse sandpaper" ! Actinic keratoses are often tactilely detected on light palpation before they are visually obvious.

Distribution : Chronic sun-exposed anatomical sites in fair-skinned individuals (Fitzpatrick skin types I-II): bald scalp, forehead, cheeks, vermilion border of the lower lip (actinic cheilitis), ears, dorsal hands, and extensor forearms.

Hypertrophic AK & Cutaneous Horn : Thick, hyperkeratotic lesions may form an elevated, conical projection of compacted keratin known as a cutaneous horn . A biopsy of the base is mandatory because up to 15% to 20% harbor invasive squamous cell carcinoma at their foundation.

Malignant Transformation Risk

Transformation Rate : The individual annual rate of malignant transformation from a single AK to invasive cutaneous squamous cell carcinoma is estimated at 0.1% to 1% per lesion per year .

Field Cancerization & Cumulative Risk : Because patients typically present with dozens of subclinical and clinical AKs across an entire sun-damaged anatomical field, the lifetime probability of developing an invasive SCC in a patient with multiple AKs reaches 10% . Furthermore, approximately 60% to 65% of all primary cutaneous squamous cell carcinomas arise directly from pre-existing actinic keratoses .

Treatment Strategies for Actinic Keratosis: Cryotherapy vs. Field Therapy

Therapeutic management is stratified into lesion-directed destruction (for isolated, discrete lesions) and field-directed therapy (for multiple lesions or extensive field cancerization). ACTINIC KERATOSIS TREATMENT SELECTION

• Assess Number of Lesions & Field
• │
• ┌─────────────────────────┴─────────────────────────┐
• ▼ ▼
• ISOLATED LESIONS (<5 Discrete) EXTENSIVE FIELD CANCERIZATION
• Cryotherapy (Liquid Nitrogen) (Multiple AKs, diffuse sun damage)
• Open spray technique │
• Freeze-thaw cycle 5-10 sec ▼
• Excellent cure (>95%) FIELD-DIRECTED PHARMACOTHERAPY
• 1. Topical 5-Fluorouracil (5-FU 5%)
• BID for 2 to 4 weeks (Gold Standard!)
• 2. Topical Imiquimod 3.75% or 5%
• 3. Photodynamic Therapy (ALA + Light)
• 1. Lesion-Directed Therapy: Liquid Nitrogen Cryotherapy

Technique : Liquid nitrogen (-196°C) applied via an open spray canister, holding the nozzle 1 cm from the lesion and freezing until a 1- to 2-mm ice halo forms around the margin, maintaining the freeze for 5 to 10 seconds , followed by complete thawing.

Indications : The first-line, gold-standard therapy for isolated, individual, discrete actinic keratoses (<5 lesions).

Mechanism & Sequelae : Intracellular ice crystal formation shears cell membranes, inducing vascular stasis and keratinocyte necrosis. Patients should be warned of blistering, crusting, and potential permanent localized hypopigmentation .

2. Field-Directed Therapy: Topical 5-Fluorouracil (5-FU)

The Concept of Field Cancerization : Chronic UV exposure induces genetic mutations throughout an entire anatomical zone (e.g., the entire bald scalp or forehead), resulting in widespread subclinical atypia surrounding visible AKs. Treating only individual visible spots leaves subclinical dysplastic cells untouched.

Topical 5-Fluorouracil (5-FU 5% Cream - Efudex) :

Mechanism : A fluorinated pyrimidine antimetabolite that irreversibly inhibits thymidylate synthase , halting thymidine nucleotide synthesis, DNA replication, and RNA processing in rapidly dividing atypical keratinocytes.

Application : Applied thinly to the entire affected anatomical field twice daily for 2 to 4 weeks .

Patient Counseling on the Expected Inflammatory Response (Crucial Board Clue!) : Clinicians must rigorously educate patients that 5-FU induces an intense, sequential four-stage inflammatory reaction:

• Erythema (days 3-7);
• Vesiculation & Blistering (days 7-14);
• Erosion, Ulceration & Necrosis (days 14-21; the skin appears severely burned and raw);

Re-epithelialization & Healing (weeks 3-6 post-treatment).

Patients must understand that this dramatic, unsightly, and uncomfortable inflammatory response is expected and directly correlates with successful eradication of premalignant cells.

3. Alternative Field Therapies

Topical Imiquimod (3.75% or 5% Cream) : An immune-response modifier that acts as an agonist at Toll-like receptor 7 (TLR-7) , stimulating local plasmacytoid dendritic cells to secrete interferon-alpha, IL-12, and TNF-alpha, triggering a T-cell-mediated antitumor immune response. Applied 2 to 3 times weekly for 4 to 16 weeks.

Photodynamic Therapy (PDT) : Topical application of a photosensitizing prodrug ( 5-aminolevulinic acid [ALA] ), which is preferentially metabolized by dysplastic keratinocytes into protoporphyrin IX. Subsequent illumination with a blue or red light source generates cytotoxic singlet oxygen free radicals, destroying atypical cells with minimal scarring.

Basal Cell Carcinoma: Subtypes, Presentation & Biopsy

Basal cell carcinoma (BCC) is the most common cancer in humans, accounting for approximately 75% to 80% of all non-melanoma skin malignancies. It arises from pluripotent stem cells in the basal layer of the interfollicular epidermis and hair follicle outer root sheath.

Molecular Drivers & Pathophysiology

The hallmark molecular driver of BCC is aberrant, constitutive hyperactivation of the Sonic Hedgehog (SHH) signaling pathway .

More than 90% of sporadic BCCs harbor loss-of-function mutations in the patched-1 ( PTCH1 ) tumor suppressor gene on chromosome 9q22, or activating mutations in the smoothened ( SMO ) proto-oncogene.

Biologic Behavior : BCC is characteristically slow-growing and locally invasive , with deep tissue destruction if neglected. However, BCC has an extremely low metastatic potential (<0.01% to 0.1%) , spreading to regional lymph nodes or lungs only in extreme, long-neglected tumors. BASAL CELL CARCINOMA SUBTYPES

• NODULAR BCC (~60%) SUPERFICIAL BCC (~20%) MORPHEAFORM BCC (~10%)
• ┌────────────────────┐ ┌────────────────────┐ ┌────────────────────┐
• │ • Pearly / Shiny │ │ • Erythematous │ │ • Scar-like / Flat │
• │ • Rolled Borders │ │ • Thin scaly patch │ │ • Indurated plaque │
• │ • Telangiectasias │ │ • Thread-like rim │ │ • Aggressive depth │
• │ • Central Ulcer │ │ • Mimics Eczema │ │ • Mohs Mandatory! │
• └────────────────────┘ └────────────────────┘ └────────────────────┘
• Clinical Subtypes

Nodular BCC (Most Common, ~60%) :

Classic morphology: A firm, pearly or translucent, pink-to-flesh-colored dome-shaped papule or nodule with raised, rolled ("donut-like") borders ;

Prominent arborizing telangiectatic vessels coursing across the surface;

As the tumor enlarges, the center frequently undergoes ischemic necrosis, developing central depression, ulceration, and crusting (the historical "rodent ulcer" ).

Superficial BCC (~15-30%) :

Presents as a well-circumscribed, slowly enlarging, erythematous, dry, scaly patch or thin plaque, often with a fine, delicate, thread-like pearly border on close inspection;

Most common on the trunk and shoulders of younger adults;

Board Diagnostic Pitfall : Frequently misdiagnosed and mistreated as eczema, psoriasis, or tinea corporis. A scaly erythematous plaque that fails to respond to topical corticosteroids warrants a biopsy.

Morpheaform (Infiltrative / Sclerotic) BCC (~5-10%) :

Presents as an indurated, firm, flat or slightly depressed, scar-like (sclerotic), ivory-white or yellowish plaque with ill-defined clinical borders;

Histologically characterized by narrow strands of basaloid cells deeply infiltrating a dense fibrous stroma;

Highly aggressive subtype with extensive subclinical microscopic extension far beyond visible clinical margins, carrying high recurrence rates.

Pigmented BCC :

Contains brown, blue, or black melanin pigment; easily confused with cutaneous melanoma.

Diagnostic Biopsy Technique for BCC

Shave Biopsy : An elevated shave biopsy or saucerization shave is the preferred initial diagnostic technique for raised, exophytic, nodular or superficial lesions. It provides adequate architectural depth while leaving a clean cosmetic base.

Punch Biopsy : Preferred for flat, indurated, morpheaform, or recurrent lesions where full-thickness dermal and subcutaneous architecture is needed to assess depth of invasion.

Management of BCC: Standard Excision, ED&C & Mohs Surgery

Selection of definitive treatment depends on tumor risk stratification based on anatomic location, tumor size, histologic subtype, and primary versus recurrent status.

Anatomic Risk Stratification: The Facial "H-Zone"

High-Risk Locations ("H-Zone" / Mask Area of Face) : Central face (eyelids, periorbital skin, nose, lips, chin, nasolabial folds), ears (auricle, retroauricular, canal), temples, preauricular cheek, hands, feet, and genitalia. High risk of subclinical invasion, recurrence, and cosmetic deformity.

Moderate-Risk Locations ("M-Zone") : Cheeks, forehead, scalp, neck, and pretibial lower extremities.

Low-Risk Locations ("L-Zone") : Trunk and extremities (excluding hands, feet, pretibial, and nails).

Therapeutic Modalities

Modality Clinical Indications Surgical Parameters & Margins Clinical Advantages & Caveats

Standard Surgical Excision Low-risk primary BCCs on trunk or extremities (L-zone) 4 mm margin of clinically normal skin excised down to subcutaneous fat >95% cure rate. Standard postoperative vertical bread-loaf histology examines <1-2% of total margin.

Electrodessication & Curettage (ED&C) Small (<1-2 cm), primary, low-risk superficial or nodular BCC on trunk/extremities 3 sequential cycles of vigorous curettage down to firm dermis followed by electrodessication Fast, cost-effective, no suturing. CONTRAINDICATED in the H-zone of face, morpheaform subtype, or recurrent tumors!

Mohs Micrographic Surgery (MMS) High-risk BCC : H-zone of face, diameter >2 cm, morpheaform/infiltrative histology, recurrent tumors, perineural invasion Sequential horizontal frozen section mapping evaluating 100% of peripheral and deep surgical margins Gold standard (highest cure: 99% primary, 95% recurrent) . Maximizes healthy tissue conservation in cosmetically critical areas.

Topical Therapy (Imiquimod or 5-FU) Superficial BCC only in low-risk trunk/extremity locations Applied 5 times weekly for 6 weeks (imiquimod) Non-surgical option for poor operative candidates. Not for nodular or morpheaform BCC.

Hedgehog Pathway Inhibitors Locally advanced, surgically inoperable, or metastatic BCC Vismodegib (150 mg PO daily) or Sonidegib (200 mg PO daily) Oral targeted SMO inhibitors. Common adverse effects: muscle spasms, dysgeusia, alopecia.

Cutaneous Squamous Cell Carcinoma: Variants & Metastatic Risk

Cutaneous squamous cell carcinoma (SCC) is the second most common skin cancer, accounting for approximately 20% of non-melanoma skin malignancies. It represents an invasive malignant proliferation of epidermal keratinocytes capable of local tissue destruction and lymphatic metastasis.

Etiology & High-Risk Patient Populations

Cumulative UV Radiation : Lifetime cumulative sun exposure is the primary driver, directly correlating with occupational outdoor work.

Solid Organ Transplant Recipients (Crucial Board Pearl!) : Immunosuppressed transplant patients have a 65- to 250-fold increased incidence of cutaneous SCC compared to the general population! In transplant recipients, SCC outnumbers BCC by 3:1 to 4:1, and tumors exhibit an exceptionally aggressive course with higher rates of recurrence and nodal metastasis.

Marjolin Ulcer : Aggressive SCC arising within chronic, non-healing wounds, burn scars, venous stasis ulcers, or osteomyelitis sinus tracts . Characterized by latency of decades and a high metastatic rate (up to 30%).

Clinical Presentation & Variants

Invasive SCC : A firm, indurated, flesh-colored to bright erythematous papule, nodule, or plaque with rough, adherent, thick hyperkeratotic scale or central ulceration with a firm, elevated, rolled margin. Frequently tender to palpation.

Bowen Disease (Squamous Cell Carcinoma in Situ) : A slowly enlarging, well-demarcated, erythematous, thin scaly plaque with irregular borders. Histology shows full-thickness epidermal dysplasia without invasion through the basement membrane.

Keratoacanthoma (KA) : Characterized by explosively rapid growth over 4 to 8 weeks , presenting as a symmetrical, dome-shaped, volcano-like nodule with a central crater filled with a prominent keratin plug . While KAs can regress spontaneously, they are biologically considered well-differentiated SCC variants and are treated with definitive surgical excision. HIGH-RISK FEATURES FOR SCC METASTASIS

• ANATOMIC LOCATION TUMOR PARAMETERS HOST & HISTOLOGY
• ┌────────────────────┐ ┌────────────────────┐ ┌────────────────────┐
• │ • Vermilion Lip │ │ • Diameter >2 cm │ │ • Organ Transplant │
• │ • Ear (Helix) │ │ • Breslow >2-4 mm │ │ • Immunosuppressed │
• │ • Perineum/Genitals│ │ • Subcutaneous fat │ │ • Perineural Inv. │
• │ • Marjolin Ulcer │ │ • Recurrent tumor │ │ • Poorly Differentiated
• └────────────────────┘ └────────────────────┘ └────────────────────┘
• Management of Cutaneous SCC

Standard Surgical Excision : For low-risk, small primary SCC on trunk/extremities: 4 to 6 mm margins of normal skin down into subcutaneous fat.

Mohs Micrographic Surgery : First-line standard of care for all high-risk SCCs (H-zone of face, diameter >2 cm, ear or lip involvement, poorly differentiated histology, perineural invasion, recurrent tumors, or organ transplant recipients).

Advanced/Metastatic SCC : Immune checkpoint inhibition with Cemiplimab or Pembrolizumab (monoclonal antibodies targeting programmed cell death-1 [PD-1]).

Melanoma Clinical Recognition: The ABCDE Criteria & Ugly Duckling Sign

Cutaneous melanoma is a malignant neoplasm arising from melanin-producing melanocytes. While accounting for only 1% to 2% of all skin malignancies, it is responsible for over 75% of skin cancer-related deaths .

Risk Factors

Intermittent, intense UV radiation exposure and history of severe, blistering sunburns in childhood/adolescence;

• Fair skin phototypes (Fitzpatrick I-II: blue/green eyes, red/blond hair, freckling propensity);
• High melanocytic nevus count (>50 common nevi or >5 atypical/dysplastic nevi);
• Personal or family history of melanoma (first-degree relative confers a 2- to 3-fold increased risk);

Genetic mutations: Germline mutations in CDKN2A (cyclin-dependent kinase inhibitor 2A, p16) or somatic mutations in BRAF (specifically the BRAF V600E mutation, found in ~50% of melanomas) .

The ABCDE Diagnostic Framework MELANOMA ABCDE CRITERIA

• [A] ASYMMETRY ──────────────> One half does not match the other half
• [B] BORDER IRREGULARITY ────> Edges are notched, scalloped, ragged, or blurred
• [C] COLOR VARIEGATION ──────> Multiple shades: brown, black, tan, blue, red, white
• [D] DIAMETER >=6 MM ────────> Larger than a pencil eraser (early may be smaller)
• [E] EVOLVING ───────────────> Documented change in size, shape, color, or symptoms
• (THE SINGLE MOST SENSITIVE CLINICAL INDICATOR!)
• The "Ugly Duckling" Sign

Most individuals have a dominant, uniform morphologic pattern for their melanocytic nevi. The "Ugly Duckling" sign posits that a pigmented lesion that looks visibly different from all the patient's other moles (an outlier in size, shade, or architecture) has an exceptionally high likelihood of representing melanoma and warrants immediate biopsy.

Clinical Subtypes

Superficial Spreading Melanoma (Most Common, ~70%) : Characterized by a prolonged initial radial (horizontal) growth phase within the epidermis before vertical invasion occurs. Classically found on the backs of men and the lower extremities of women.

Nodular Melanoma (~15-20%) : Characterized by an immediate vertical growth phase from inception without a preceding radial phase. Presents as a rapidly enlarging, darkly pigmented or amelanotic (pink/flesh-colored) dome-shaped nodule that frequently ulcerates and bleeds; carries a poor prognosis due to rapid deep invasion.

Lentigo Maligna / Lentigo Maligna Melanoma (~5-15%) : Arises on chronically sun-damaged skin of elderly individuals (face, neck, forearms) as a slow-growing, large, flat, asymmetric mottled brown patch (Lentigo Maligna = melanoma in situ).

Acral Lentiginous Melanoma (~2-5%) :

Located on palmar, plantar, or subungual nail bed skin;

The most common subtype of melanoma in individuals with darker skin phototypes (African, Asian, and Hispanic populations), accounting for up to 50% to 70% of melanomas in these groups;

Not associated with UV radiation ;

Hutchinson Sign : Longitudinal melanonychia (pigmented longitudinal nail band) with extension of black or brown pigment onto the adjacent proximal or lateral periungual nail fold, highly suspicious for subungual melanoma.

Diagnostic Biopsy Principles: The Excisional Gold Standard

Important

THE GOLD-STANDARD BIOPSY TECHNIQUE FOR SUSPECTED MELANOMA When a pigmented lesion exhibits ABCDE criteria or an "Ugly Duckling" appearance, the preferred initial diagnostic procedure is a COMPLETE NARROW EXCISIONAL BIOPSY with a 1 to 3 mm margin of normal skin, extending into the subcutaneous fat .

If the lesion is too large for primary complete excision, or is situated in a cosmetically sensitive site (face, digit), a full-thickness punch biopsy or deep incisional punch biopsy of the thickest, darkest, most clinically raised portion is acceptable.

NEVER PERFORM A SUPERFICIAL SHAVE BIOPSY ON A SUSPECTED MELANOMA!

Performing a superficial horizontal shave biopsy transects the deep margin of the tumor, destroying the basement architecture and preventing the pathologist from accurately measuring the full Breslow depth .

Transection leads to inaccurate microstaging, false understaging, and inappropriate definitive treatment planning.

Cryotherapy is strictly contraindicated for any undiagnosed suspicious pigmented lesion.

• Breslow Thickness, Surgical Margins & Sentinel Node Biopsy
• Breslow Depth: The Master Prognostic Indicator

Measurement : Histologic vertical depth measured in millimeters from the top of the epidermal granular cell layer (or base of ulceration) down to the deepest invasive malignant melanocyte in the dermis or subcutaneous fat.

Significance : Breslow depth is the single most powerful prognostic factor for primary localized cutaneous melanoma .

Definitive Surgical Wide Local Excision Margins

Once the primary biopsy confirms melanoma and provides the Breslow depth, definitive wide local excision must be performed with specific, evidence-based surgical margins measured radially from the lesion's edge:

• Melanoma Stage & Breslow Depth Definitive Surgical Margin Depth of Excision
• Melanoma in Situ (Epidermis only) 0.5 cm to 1.0 cm Down to subcutaneous tissue
• Breslow Depth < 1.0 mm (Thin melanoma) 1.0 cm Down to, but not including, deep muscular fascia
• Breslow Depth 1.01 to 2.0 mm (Intermediate) 1.0 cm to 2.0 cm Down to, but not including, deep muscular fascia
• Breslow Depth > 2.0 mm (Thick melanoma) 2.0 cm Down to, but not including, deep muscular fascia
• Sentinel Lymph Node Biopsy (SLNB) Indications

Sentinel lymph node biopsy is a specialized staging procedure utilizing radioactive radiotracer (Technetium-99m) and isosulfan/methylene blue dye to identify and biopsy the first draining lymph node(s) receiving lymphatic flow from the primary tumor site.

Indications for SLNB :

Breslow Depth >= 1.0 mm : Routine recommendation for all clinically node-negative patients (Stage IB and Stage II);

Breslow Depth 0.8 to 1.0 mm WITH High-Risk Features : Recommended if tumor ulceration is present or if mitotic rate is elevated (>=1/mm²);

Breslow Depth < 0.8 mm : SLNB is NOT routinely recommended because the probability of nodal micrometastasis is <5%, and SLNB does not confer survival benefit.

Adjuvant & Advanced Systemic Therapies

Targeted Therapy : For patients with Stage III/IV melanoma harboring a BRAF V600E or V600K mutation , combined oral therapy with a BRAF inhibitor ( Dabrafenib ) and a MEK inhibitor ( Trametinib ) blocks downstream MAPK signaling, producing high initial response rates.

Immune Checkpoint Inhibitors : Monoclonal antibodies targeting PD-1 ( Pembrolizumab , Nivolumab ) or CTLA-4 ( Ipilimumab ) unleash cytotoxic T-cell antitumor immunity, dramatically extending long-term overall survival in advanced melanoma.

Loading diagram... Diagnostic Triage and Surgical Decision Algorithm for Premalignant and Malignant Skin Lesions